Buchumschlag

Ethnic Bridging of Sepiapterin in Chinese and Korean Populations Based on Predictions From Genetic Polymorphism of Breast Cancer Resistance Protein

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Lan Gao, Neil Smith, Ronald Kong
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Clinical and Translational Science
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Population Pharmacokinetics and Exposure–Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer
von: Carlos Fernandez Teruel, et al.
Veröffentlicht: (2025)

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma
von: Junyi Li, et al.
Veröffentlicht: (2025)

Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population
von: Sayanit Tipnoppanon, et al.
Veröffentlicht: (2025)

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
von: Jason D. Kim, et al.
Veröffentlicht: (2026)

AI ‐Driven Variant Annotation for Precision Oncology in Breast Cancer
von: Kriti Shukla, et al.
Veröffentlicht: (2025)

Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
von: Tvisha Devireddy, et al.
Veröffentlicht: (2025)

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients
von: Kun Wang, et al.
Veröffentlicht: (2025)

Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients
von: Anitha Saravanakumar, et al.
Veröffentlicht: (2026)

Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives
von: Tamás Sass, et al.
Veröffentlicht: (2025)

Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
von: Nicki M. Kyriacou, et al.
Veröffentlicht: (2025)

Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data
von: Leping Kong, et al.
Veröffentlicht: (2026)

Standardization, Education, and Resourcing: The Way Forward for Implementing Polygenic Risk Scores in Hereditary Breast and Ovarian Cancer
von: Rebecca Purvis, et al.
Veröffentlicht: (2025)

Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis
von: Cindy X. Zhang, et al.
Veröffentlicht: (2025)

Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin
von: Sayanit Tipnoppanon, et al.
Veröffentlicht: (2026)

Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics
von: Hui Yu, et al.
Veröffentlicht: (2025)

Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis
von: Atul Rawal, et al.
Veröffentlicht: (2025)

Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches
von: Zoey Tang, et al.
Veröffentlicht: (2026)

CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI
von: Diona Gjermeni, et al.
Veröffentlicht: (2026)

Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study
von: Leila Potzel, et al.
Veröffentlicht: (2026)

Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma
von: Cheryl Li, et al.
Veröffentlicht: (2025)

The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol
von: Stefania Braidotti, et al.
Veröffentlicht: (2025)

Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects
von: Young‐Sim Choi, et al.
Veröffentlicht: (2025)

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi‐physiologic population pharmacokinetic approach
von: Juyoung Khwarg, et al.
Veröffentlicht: (2024)

Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6 ‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans
von: Sungyeun Bae, et al.
Veröffentlicht: (2026)

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
von: Xianglei Gao, et al.
Veröffentlicht: (2024)

Clinical Characteristics, Molecular Diagnosis, and Drug Resistance Profiles of Nontuberculous Mycobacteria Infections: A Retrospective Analysis Using PCR Melting Curve Technology
von: Kedi Wang, et al.
Veröffentlicht: (2026)

Effect of Whole‐Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis
von: Xudong Zhang, et al.
Veröffentlicht: (2025)

Population Pharmacokinetic Model‐Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram‐Positive Sepsis
von: Alžběta Zavřelová, et al.
Veröffentlicht: (2025)

Leveraging [ 18 F ]F‐Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer
von: Suzanne van der Gaag, et al.
Veröffentlicht: (2026)

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201 : Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer
von: Nadine Norton, et al.
Veröffentlicht: (2025)

EDP‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults
von: Kimberly Elmore, et al.
Veröffentlicht: (2025)

Genetics of Response to Canagliflozin ( GRC ) Study: Rationale, Design, and Pharmacodynamic Responses
von: May E. Montasser, et al.
Veröffentlicht: (2026)

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers
von: Bhagwat Prasad
Veröffentlicht: (2026)

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
von: Guihong Yang, et al.
Veröffentlicht: (2024)

Role of Trimethylamine N‐Oxide in Assessing Plaque Instability of the Culprit Lesion in Chinese Patients With ST ‐Elevation Myocardial Infarction: Insights From a 7‐Year Long‐Term Follow‐Up Study
von: Lili Xiu, et al.
Veröffentlicht: (2025)

Predicting the exposure of mycophenolic acid in children with autoimmune diseases using a limited sampling strategy: A retrospective study
von: Ping Zheng, et al.
Veröffentlicht: (2024)

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
von: Huijun Chen, et al.
Veröffentlicht: (2024)

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies
von: Tomohiro Kamimura, et al.
Veröffentlicht: (2024)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
von: Ngoc Hoa Truong, et al.
Veröffentlicht: (2025)

Real‐World Impact of Amiodarone on Apixaban Population Pharmacokinetics in Hospitalized Patients
von: Samantha Kolowrat, et al.
Veröffentlicht: (2025)